These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30117091)

  • 41. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
    Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
    Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
    Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinically staged cT2 adenocarcinomas of the gastroesophageal junction: accuracy of staging and therapeutic consequences.
    Vallböhmer D; Sisic L; Blank S; Kraus S; Stoecklein NH; Knoefel WT; Büchler MW; Ott K
    Oncol Res Treat; 2014; 37(3):97-104. PubMed ID: 24685912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
    Inoue K; Nakane Y; Kogire M; Fujitani K; Kimura Y; Imamura H; Tamura S; Okano S; Kwon AH; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Eur J Surg Oncol; 2012 Feb; 38(2):143-9. PubMed ID: 22154885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
    Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
    Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
    Boulikas T; Stathopoulos GP; Volakakis N; Vougiouka M
    Anticancer Res; 2005; 25(4):3031-9. PubMed ID: 16080562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in the Management of Gastric and Gastroesophageal Cancers.
    Kamran SC; Hong TS; Wo JY
    Curr Oncol Rep; 2016 Feb; 18(2):13. PubMed ID: 26769118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
    BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative effectiveness in esophagogastric cancer.
    Knab LM; Belotte J; Munshi HG; Bentrem DJ
    Cancer Treat Res; 2015; 164():121-42. PubMed ID: 25677022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report].
    Nemoto H; Takeuchi S; Yoshizawa Y; Uemichi O; Sasaya S; Yamaguchi M; Makuuchi M; Midorikawa T; Sanada Y; Kumada K; Takizawa K
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1149-53. PubMed ID: 11525035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
    Samel S; Hofheinz R; Hundt A; Sturm J; Knoll MR; Wenz F; Queisser W; Post S
    Onkologie; 2001 Jun; 24(3):278-82. PubMed ID: 11455222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus.
    Kleinberg L; Brock M; Gibson M
    Curr Treat Options Oncol; 2015 Jul; 16(7):35. PubMed ID: 26112428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
    Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
    Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
    Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
    Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A Case of Esophagogastric Junction Adenocarcinoma with Neuroendocrine Differentiation].
    Kitano Y; Kinoshita J; Oyama K; Okamoto K; Sakai S; Makino I; Nakamura K; Hayashi H; Inokuchi M; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fushida S; Ohta T
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1226-1228. PubMed ID: 29394589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer.
    Haverkamp L; Seesing MF; Ruurda JP; Boone J; V Hillegersberg R
    Dis Esophagus; 2017 Jan; 30(1):1-7. PubMed ID: 27001442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.